文献速递慢性肾脏病

多病共存CKD患者中肾衰竭风险方程的竞争性死亡风险影响

The kidney failure risk equation in people with CKD and multimorbidity: the effect of competing mortality risks.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

本研究在UK Biobank和SCREAM队列中验证四变量肾衰竭风险方程(KFRE)在伴或不伴多病共存的CKD患者中的表现,并更新模型以考虑竞争性死亡风险。结果显示KFRE判别力良好,但在多病共存者中校准不佳,更新模型可改善校准。

要点

  • 多病共存CKD患者中KFRE判别力良好但校准欠佳
  • 使用胱抑素C与肌酐计算eGFR未改善模型表现
  • 考虑竞争性死亡风险的更新模型校准表现更优

核心结论

  • 竞争性死亡风险在预测肾衰竭时重要,尤其对多病共存者。
  • 考虑竞争性死亡风险的更新模型可改善模型表现。

研究设计与样本

  • 观察性队列研究,使用UK Biobank和SCREAM人群队列。
  • 多病共存定义为除CKD外有两种及以上长期疾病。
  • 肾衰竭定义为长期透析或肾移植。
  • 评估KFRE在2年和5年的判别力、校准和整体拟合。
  • 开发并验证考虑竞争性死亡风险的更新模型(使用与KFRE相同的变量)。

主要发现

  • KFRE判别力良好,所有队列、多病共存组和时间点AUC≥0.86(各eGFR方程)。
  • UK Biobank多病共存组5年肾衰竭风险被低估,O/E比1.75(eGFR肌酐)。
  • SCREAM多病共存组5年O/E比1.05(eGFR肌酐)。
  • 使用胱抑素C相比肌酐未改善模型表现。

关键数值与推荐

  • KFRE判别力AUC≥0.86(所有队列、多病共存组、2年和5年)。
  • UK Biobank多病共存组5年O/E比1.75(eGFR肌酐)。
  • SCREAM多病共存组5年O/E比1.05(eGFR肌酐)。
  • 更新模型在UK Biobank多病共存组5年O/E比0.98。

临床怎么用

  • 对多病共存CKD患者使用KFRE预测肾衰竭时需注意风险可能被低估。
  • 可考虑使用考虑竞争性死亡风险的更新模型以改善校准。
  • 选择肌酐或胱抑素C计算eGFR对KFRE表现无显著影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Guidelines recommend using risk prediction models for predicting kidney failure in chronic kidney disease (CKD). Many people with CKD have multiple long-term conditions (multimorbidity), which influences outcomes including kidney failure and mortality. This study validated the four-variable kidney failure risk equation (KFRE) in individuals with CKD, with and without multimorbidity, comparing performance of KFRE using creatinine and cystatin C to calculate estimated glomerular filtration rate (eGFR) and updated the model to account for competing mortality risks. METHODS: Observational cohort study using research-based (UK Biobank) and population-based cohorts (Stockholm Creatinine Measurements project: SCREAM). Multimorbidity was defined as two or more long-term conditions in addition to CKD. Kidney failure was defined as long-term dialysis or kidney transplantation. KFRE performance assessment included discrimination, calibration, and overall fit at 2 and 5 years. An updated model (using the same variables as KFRE) accounting for competing mortality risks was developed and validated. RESULTS: 14 998 of 24 489 individuals in UK Biobank (61.2%) and 30 147 of 42 902 individuals in SCREAM (70.3%) had multimorbidity. Discrimination of KFRE was good (area under curve $\ge $0.86 across eGFR equations in all cohorts, multimorbidity groups and time horizons). Kidney failure risk was under-estimated in people with multimorbidity in UK Biobank (observed/expected (O/E) ratio 1.75 at 5 years; eGFR creatinine). Conversely, calibration-in-the-large (O/E ratio) at 5 years in SCREAM was 1.05 in the multimorbidity group (eGFR creatinine). Using cystatin C compared to creatinine did not improve model performance.Cumulative incidence of death was higher with multimorbidity compared to no multimorbidity. An updated model considering competing mortality improved calibration performance over KFRE, O/E ratio 0.98 in multimorbidity group of the validation cohort (UK Biobank) at 5 years. CONCLUSION: Competing mortality risk is important when predicting kidney failure, particularly for people with multimorbidity. An updated model accounting for competing mortality risk, permits improved model performance.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Walker H, Carrero JJ, Sullivan MK, et al. The kidney failure risk equation in people with CKD and multimorbidity: the effect of competing mortality risks. Nephrol Dial Transplant. 2026. PMID: 41288315. doi:10.1093/ndt/gfaf252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。